# Rifaximin and Norfloxacin for Prevention of SBP in Adults With Decompensated Cirrhosis

> **NCT03695705** · PHASE3 · COMPLETED · sponsor: **Post Graduate Institute of Medical Education and Research, Chandigarh** · enrollment: 142 (actual)

## Conditions studied

- Cirrhosis, Liver

## Interventions

- **DRUG:** Rifaximin 550 mg twice a day and Norfloxacin 400 mg once a day

## Key facts

- **NCT ID:** NCT03695705
- **Lead sponsor:** Post Graduate Institute of Medical Education and Research, Chandigarh
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-01-01
- **Primary completion:** 2016-12-31
- **Final completion:** 2017-06-30
- **Target enrollment:** 142 (ACTUAL)
- **Last updated:** 2018-10-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03695705

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03695705, "Rifaximin and Norfloxacin for Prevention of SBP in Adults With Decompensated Cirrhosis". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03695705. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*